GENFIT Showcases Elafibranor Efficacy in PSC at EASL 2025

GENFIT's Promising Results for Elafibranor in PSC

GENFIT, a biopharmaceutical enterprise focused on rare and life-threatening liver conditions, has exciting news to share. Recent data from a late-breaking abstract on elafibranor, which is under development for Primary Sclerosing Cholangitis (PSC), will be highlighted by Ipsen during the European Association for the Study of the Liver (EASL) Congress in 2025. This research unveils a favorable safety profile along with significant efficacy, promising enhancements for patients suffering from this serious condition.

Details from the Latest Research

The Phase 2 ELMWOOD trial provided compelling efficacy results, indicating that patients receiving elafibranor experienced noteworthy dose-dependent reductions in alkaline phosphatase (ALP) levels. Particularly, patients on elafibranor doses of 80 mg and 120 mg exhibited significant decreases at week 12 compared to placebo, marking reductions of ?103.2 U/L and ?171.1 U/L, respectively. Mirroring this trend, noticeable improvements surfaced by week 4. In addition, markers like alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), crucial indicators of liver disease progression, displayed similar positive trends. Furthermore, elafibranor facilitated stabilization in Enhanced Liver Fibrosis (ELF) scores, a vital non-invasive marker, versus placebo at week 12.

Improvements in Patient Comfort

Patients undergoing treatment with elafibranor 120 mg also reported alleviation of pruritus, pain associated with itching, demonstrating statistical significance on the Worst Itch Numeric Rating Scale. This aspect of patient comfort is critical, especially for those dealing with the distressing symptoms of PSC.

Understanding Elafibranor

Elafibranor is heralded as a groundbreaking medication, recently branded as Iqirvo®, and has been authorized for use in the treatment of Primary Biliary Cholangitis (PBC) since June 2024. Developed by GENFIT, it was licensed to Ipsen, ensuring a broad distribution across the US and Europe, excluding certain Asian regions. Elafibranor works through mechanisms that activate peroxisome proliferator-activated receptors (PPAR), leading to improved metabolic processes and reduced bile toxicity, thus addressing cholestasis effectively.

Expert Insight

Pascal Prigent, the CEO of GENFIT, expressed optimism regarding these results, stating, "Ipsen's dedication to advancing elafibranor underlines its potential impact on tackling severe liver diseases. The results from the ELMWOOD Phase 2 trial reinforce our confidence in its capabilities to make significant improvements in patient outcomes."

A Closer Look at Primary Sclerosing Cholangitis

PSC is classified as a rare, chronic liver disease which involves inflammation and scarring of bile ducts, leading to serious liver damage and eventual failure. Although the root cause of PSC remains unclear, it’s commonly linked with other autoimmune disorders. Patients often face a multitude of challenges, including debilitating symptoms such as jaundice, persistent fatigue, itching, and abdominal discomfort. The absence of FDA-approved treatments for PSC emphasizes the importance of the findings from this and future studies.

GENFIT's Vision

GENFIT is dedicated not only to the development of innovative therapies but also to understanding rare liver diseases deeply. They maintain a robust research and development portfolio aimed at conditions like Acute-on-Chronic Liver Failure, with several promising projects currently underway. By focusing on comprehensive treatments and diagnostic tools, GENFIT is at the forefront of advancing liver health.

Contact and Further Information

For inquiries, GENFIT encourages reaching out to their team. Investors can contact the company via telephone or email, while media inquiries are directed to dedicated press relations personnel. Their commitment to progress and transparency in the field of liver diseases shines through their outreach strategy and continued R&D investments.

Frequently Asked Questions

What is elafibranor and how does it work?

Elafibranor is an oral medication that acts as a PPAR agonist, modulating bile acid synthesis and exhibiting anti-inflammatory effects, particularly beneficial in liver diseases.

What are the implications of the recent ELMWOOD trial results?

The trial's results suggest elafibranor significantly reduces liver enzyme levels and improves symptoms, indicating potential therapeutic benefits for PSC patients.

Why is PSC a critical condition with unmet medical needs?

PSC is a rare liver illness lacking FDA-approved treatments, leading to significant health complications, which underscores the importance of new therapies like elafibranor.

How does GENFIT support liver health research?

GENFIT invests heavily in R&D, focusing on various liver conditions, aiming to bring effective treatments and diagnostics to market for patients in need.

Where can I find more information about GENFIT?

Details on GENFIT's research, products, and corporate activities are available on their official website, where they provide resources for both investors and the media.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.